Brochure | Cardiovascular Diseases

Human Papillomavirus (HPV) and Cardiovascular Risk

2025-04-01 - 2025-04

Recent research indicates a significant association between HPV infection and increased heart disease risk. Individuals testing positive for HPV were found to have a 40% higher likelihood of developing cardiovascular disease and double the risk of coronary artery disease compared to those without the infection. This underscores the importance of HPV vaccination and monitoring for cardiovascular health.

Experimental Drug Shows Promise in Reducing Genetic Heart Disease Risk

2025-03-31 - 2025-03

Eli Lilly's experimental drug, lepodisiran, has demonstrated a significant reduction in lipoprotein(a) (Lp(a)) levels—a genetic risk factor for heart disease—by an average of 93.9% compared to placebo in a mid-stage trial. The study involved 141 patients receiving a 400 mg dose of lepodisiran and 69 receiving a placebo over six months, with no serious drug-related complications reported. These findings were presented at the American College of Cardiology meeting in Chicago and published in the New England Journal of Medicine.

HPV Infection and Heart Disease Risk

2025-03-28 - 2025-03

Recent studies have identified a significant association between human papillomavirus (HPV) infection and an increased risk of cardiovascular diseases. Individuals testing positive for HPV were found to have a 40% higher likelihood of developing cardiovascular conditions and double the risk of coronary artery disease compared to those without the infection. Researchers suggest that chronic inflammation caused by HPV may contribute to this elevated risk, highlighting the potential cardiovascular benefits of HPV vaccination.

New Cardiology Board Denied but ‘Not Done With This Fight’

2025-03-27 - 2025-03

Leaders of a group convened to establish a new, independent board for cardiology are reviewing options after the American Board of Medical Specialties (ABMS) rejected their application to establish the American Board of Cardiovascular Medicine and invoked a 2-year wait time to reapply.

New Evidence Links Microplastics with Chronic Disease

2025-03-26 - 2025-03

Tiny fragments of plastic have become ubiquitous in our environment and our bodies. Higher exposure to these microplastics, which can be inadvertently consumed or inhaled, is associated with a heightened prevalence of chronic noncommunicable diseases, according to new research being presented at the American College of Cardiology's Annual Scientific Session.

Smartwatches in Cardiovascular Monitoring

2025-03-24 - 2025-03

Research from Northwestern University Feinberg School of Medicine indicates that smartwatches can monitor heart health by tracking heart rate per step. An elevated daily heart rate per step (DHRPS) is associated with higher risks of type 2 diabetes, heart failure, high blood pressure, and coronary atherosclerosis. This suggests that smartwatch data could encourage individuals to seek medical advice and undergo further cardiovascular screening.

Webinar on Cardiovascular Diseases and Therapeutics

Brochure Form

useful links

Latest News

Human Papillomavirus (HPV) and Cardiovascular Risk

Experimental Drug Shows Promise in Reducing Genetic Heart Disease Risk

HPV Infection and Heart Disease Risk

New Cardiology Board Denied but ‘Not Done With This Fight’

New Evidence Links Microplastics with Chronic Disease

Smartwatches in Cardiovascular Monitoring

cardiology@confmeets.net

support@confmeets.net

+44 789 707 2181